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the findings obtained in necropsy studies. Information
collated from five independent necropsy studies indicated
that mean prostate weight reaches 20 g in men between the
ages of 21 and 30 years and remains essentially constant at
this weight with increasing age unless BPH develops.1O
Table II summarises the prevalence rates of BPH and
prostatic weights of patients with BPH in the survey in
comparison with necropsy findings among men in similar
age-groups with histologically confirmed BPH. A
surprising finding is that prostatic weights from these two
sources are remarkably similar despite the differences in
self-selection betwen the community survey and necropsy
sources, the absence of prior knowledge of urinary
dysfunction in the necropsy cases, and the absence of
pathological confirmation of the diagnosis in the community
survey. What is also of interest are the higher age-specific
rates for BPH in the necropsy than in the community
survey. This difference suggests that a substantial reservoir
of BPH may exist below the "threshold" of signs and
symptoms of urinary dysfunction that were used in the
survey. The operational defmition adopted for this survey
will probably change over time as knowledge of the natural
history of BPH increases, in the way that perception of what
level of blood pressure constitutes hypertension has changed
over the past several decades.
Whether the total urinary symptom score and Qmax
cut-off points used are ideal for enabling early cases of BPH
to be picked up through screening cannot be established
from this survey. This issue can be determined only in a
study that sets out to assess prostate size in a representative
sample of men who have not been selected on the basis of
their likelihood of having BPH. The validity of symptom
scores and voiding flow rate as preliminary screening criteria
will eventually be required for identifying those men most
likely to benefit from treatment should non-surgical therapy
for BPH be shown to be effective in the community.
We thank the consultant urologists and other staff of Stirling Royal
Infirmary, the general practitioners and their staff at Bridge of Allan Health
Centre, the Forth Valley General Practitioner Research Group, and all other
members of the BPH Natural History Study Group for their advice,
cooperation, and support. Funding for this work was provided by Merck,
Sharp & Dohme.
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ampicillin in mild acute respiratory infections in
Indonesian children
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The recommended treatment for mild acute
respiratory infections (ARI) in children is supportive
care only, but many physicians, especially in
developing countries, continue to prescribe
antibiotic treatment because they believe it prevents
progression to more severe ARI. To find out whether
ampicillin treatment conferred any benefit over
supportive care alone, a randomised, controlled trial
was carried out among 889 children (under 5 years)
with mild ARI in Indonesia. 447 were randomly
allocated ampicillin (25-30 mg/kg body weight
three times daily for 5 days) plus supportive care
(continued breastfeeding, clearing of the nose, and
paracetamol to control fever); 442 were allocated
supportive care only. The treatment groups were
almost identical after randomisation in terms of age,
sex, level of parental education, history of measles
immunisation, and fever. After 1 week the
percentages cured were nearly identical (204 [46%]
ampicillin; 209 [47%] control), as were the
percentages of cases progressing to moderate ARI
(56 [13%] vs 53 [12%]). The effect of treatment was
not modified by age, sex, measles immunisation
status, or the educational level of the parents. At the
2-week follow-up, the percentages cured were 62%
(277) in the ampicillin group and 58% (256) in the
control group; 14% of both groups had progressed to
moderate ARI; and 24% (107) and 28% (123),
respectively, still had mild ARI. None of the
differences in outcome between the ampicillin and
control groups was statistically significant. Thus,
ampicillin plus supportive care offers no benefit over
supportive care alone for treatment of mild ARI in
young Indonesian children.
Introduction
Acute respiratory infections (ARI) are common in
children throughout the developing world. The infection
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may start in the upper respiratory tract and progress to a
more severe lower respiratory infection, such as pneumonia
or bronchiolitis.l In less developed countries, pneumonia is
a major cause of death in young children 2-4 Antibiotics such
as procaine penicillin, ampicillin, or co-trimoxazole are
useful for treatment of pneumonia1,5,6 which is most
commonly caused by bacterial agents, mainly Streptococcus
pneumoniae and Haemophilus influenzae.1,5,7,8 Antibiotics are
not recommended for treatment of upper respiratory
infections which are believed to be caused mainly by
viruses, most likely rhinoviruses and coronaviruses.9
The World Health Organisation (WHO) has promoted
case-management as the appropriate approach to control of
ARI in children.7,10 Part of this recommendation is that
supportive care by the mother rather than antibiotics be
used to treat mild ARI. Inappropriate treatment of mild
ARI in developing countries wastes the resources of
government-sponsored health services and is believed to
increase the occurrence of drug-resistant bacterial strains in
the population."
When the WHO case-management programme was
introduced in Indonesia, many physicians were reluctant to
stop giving antibiotics to children with mild ARI, because
they believed that antibiotic treatment prevents the
progression of mild ARI to moderate or severe ARI. This
belief is not supported by any objective evidence. We
decided to test the effectiveness of antibiotics for treatment
of mild ARI in Indonesian children. We now present the
results from a randomised, controlled comparison of
supportive care alone and ampicillin plus supportive care as
treatment for mild ARI in children under 5 years of age. We
chose ampicillin on the basis of our earlier findings that 70%
of Indonesian physicians who treated mild ARI with
antibiotics used ampicillin (unpublished).
Subjects and methods
900 children under 5 years of age with mild ARI, who attended
government health clinics in two regions of East Jakarta, Indonesia,
were included in the trial. Mild ARI was defined by WHO criteria:
mild upper respiratory signs such as cough or runny nose, and/or
fever ( > 37&deg;C), and breathing at a rate less than 50 breaths per minute.
We excluded children with asthma or infections that required
antibiotics, those who did not live in a defined service area, and those
who had recently been treated by medical personnel in other
locations. Parental consent was obtained for all eligible children.
Through random allocation, 451 children were offered ampicillin
powder and supportive care and 449 were offered only supportive
care. Parents in both groups were advised to provide supportive care
at home including continuation of breastfeeding, clearing of the
nose as needed, and control of mild fever by means of paracetamol,
an inexpensive analgesic and antipyretic drug (30 mg/kg body
weight daily; 3 doses per day for 5 days). In addition to the
supportive care, children in the ampicillin group received ampicillin
powder (age-dependent treatment packets of 25-30 mg/kg body
weight per dose every 6 h [except midnight] for 5 days).
Parents were asked to bring their child back to the health centre
after 5 days. Home visits were made by nurses or midwives within 2
days to children who did not appear at the clinic on the scheduled
day. Based on the clinic or home examination the health status was
classified as: cured or recovered; static (no change); worse (moderate
or severe ARI); or dead. Moderate and severe ARI were defined
according to WHO and Ministry of Health criteria.7 Moderate ARI
was diagnosed if there was a respiratory rate greater than 50 breaths
per minute but no chest indrawing, and severe ARI if the child had a
respiratory rate greater than 50 breaths per minute and chest
indrawing, with or without cyanosis. Children not cured after 1
week were either referred to the health clinic for further medical care
or sent home with instructions for additional supportive care. All
TABLE I-CHARACTERISTICS OF CHILDREN WITH MILD ARI AT
BASELINE
No (%)
children were observed by a nurse or midwife 1 week later either at
the clinic or at home.
11 children (4 ampicillin, 7 control) had stopped taking ampicillin
or paracetamol because of side-effects (diarrhoea in 10 [4 ampicillin,
6 control] and an allergic reaction in 1 [control]).
Statistical analyses were done by means of ’Epi Info’12 and ’Epi
Log Plus’, 13 two microcomputer-based statistical analysis programs
for epidemiology. These included standard chi-square tests (two
sided) and confidence intervals for risk ratios (Taylor series 95%
confidence limits).
Results
The randomisation procedure successfully achieved two
nearly identical groups in terms of the potential confounding
variables of age, sex, level of parental education, history of
measles immunisation, or fever at the time of enrolment
(table 1). After 1 week, the percentages of children who were
cured, still had mild ARI, or had progressed to moderate
ARI in the two groups were almost identical (table n). There
was no significant difference in the course of the disease
between the ampicillin-treated and control groups at either
1-week follow-up (&khgr;2=0.25, 2 df; p=0-88) or 2-week
follow-up (X2 =1-91, 2 df; p = 0-38) (table II). After 1 week
the percentage cured was similar at all ages, in both sexes, at
various education levels for fathers and mothers, and by
measles immunisation status (table III). Ampicillin appeared
beneficial only among a few subgroups, but in each case the
95 % confidence intervals included 1 -0, so the risk ratios are
more likely to reflect variation inherent in the sampling
process rather than a real benefit of ampicillin.
TABLE II-CLINICAL OUTCOME OF MILD ARI
4 amplclllm-treated and 7 control children was excluded during week 1 with
secondary disorders
*Recelved ampicillin for 5 days m wk 1
tRemoved from trial and sent to health clinic for further medical care
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TABLE III-MILD ARI CASES CURED AT 1 -WEEK FOLLOW-UP
*Likelihood of bemg cured m ampicillin group compared with control group; 95%
CI = confidence mterval
tExcludes 21 cases with unknown measles immunisation history (12 ampicillin, 9
control)
The percentage of cases of mild ARI that progressed to
moderate ARI at the 1-week follow-up was also similar in the
various subgroups (table IV). In some subgroups the control
cases were more likely to progress, whereas in others the
ampicillin-treated cases were more likely to become worse.
The width of the confidence intervals makes it unlikely that
any of the group-specific values are truly different.
After 2 weeks, 24% of ampicillin-treated and 28% of
control children still showed signs of mild ARI (table II).
14% in each group had progressed to moderate ARI and
were referred to the health clinic for additional care. The
remaining 58% of controls and 62% of ampicillin-treated
children were cured of ARI, and nearly three-quarters of
them had recovered during the first week.
TABLE IV-PROGRESSION TO MODERATE ARI AT 1-WEEK
FOLLOW-UP
*Risk of progresion to moderate ARI m ampicillin group compared wrth control
group
tExcludes 21 cases with unknown measles immunisation history (12 ampiallin,
9 control)
Discussion
The randomisation process in our study effectively
created two groups with the same inherent risk of ARI
outcome independent of treatment. Thus, we were able to
assess the unconfounded effect of ampicillin plus supportive
care compared with supportive care alone on mild ARI. We
conclude that there is no beneficial effect of ampicillin on the
clinical course of mild acute respiratory infections among
young Indonesian children. For children breathing less than
50 times per minute and showing minor signs such as a
cough or runny nose, addition of ampicillin to simple
supportive care supplemented with paracetamol conferred
no benefit.
Since mild ARI is primarily or entirely caused by viruses,
our finding that ampicillin is of no benefit for such illnesses
is hardly surprising, and readers might wonder why we
undertook this study. In our previous work on ARI in
Indonesia (unpublished), we observed that many children
with mild ARI were being treated with ampicillin by
physicians at Government clinics despite the Ministry of
Health guidelines (which accord with WHO
recommendations) that only supportive care is required.14
In our discussions with physicians, it became clear that
many believed antibiotics were effective at preventing the
progression of mild ARI to pneumonia or other forms of
severe ARI, which are frequently bacterial in origin. When
challenged to present data refuting this notion, we were
unable to find support in the Indonesian medical or public
health literature. Thus, we felt it necessary to assess in
Indonesia the effect of antimicrobial therapy on progression
of mild ARI to more severe forms. Clinical studies of
antibiotic effectiveness have been carried out in other nearby’
countries-for example, Thailand and Australia.15,16 These
studies of children with upper (or mild) respiratory
infections showed no therapeutic value for ampicillin,
erythromycin, penicillin, or tetracycline.
Although our data clearly show that the use of ampicillin
for mild ARI had no beneficial effect, what is not evident is
the potential harmful effects of inappropriate antibiotic use.
First, ampicillin used for mild ARI will not be available to
treat moderate or severe ARI. If there is a limited supply of
antibiotics, as is the case in many government health clinics,
the resultant shortage could lead to the use of less effective
treatment and higher case-fatality for moderate and severe
ARI. Even if antibiotics are widely available, use of
ineffective treatment for many mild ARI cases will
substantially reduce the cost-effectiveness of ARI
treatments in general. Second, routine use of antibiotics for
common disorders such as mild ARI may contribute to the
emergence of drug-resistant bacterial strains, which may
become difficult, if not impossible, to treat. In a study of
susceptibility of Haemophilus species to antimicrobial drugs,
6% of 426 isolates from around the world were resistant to
ampicillin.5 Although this percentage is not great, continued
indiscriminate use of antibiotics for minor respiratory
ailments can only lead to more resistance.
In summary, our results show that there is no justification
for use of ampicillin to treat mild ARI among Indonesian
children. This practice is both expensive and potentially
harmful and is not in the interests of the medical
community, the Ministry of Health, or the Indonesian
people.
This study was supported by the United States Agency for International
Development through subcontractual agreements with the Center for
Human Services (PRICOR); Center for Child Survival, University of
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Indonesia; and the Western Consortium for Public Health, Inc. We thank
Prof M. C. Steinhoff for helpful comments.
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SHORT REPORTS
Phylogeny of the Whipple’s-
disease-associated bacterium
Efforts to culture and identify the intracellular
bacteria associated with Whipple’s disease have
been unsuccessful. Nucleotide sequencing and
amplification by the polymerase chain reaction was
done on the bacterial 16 S ribosomal DNA present in
a small-bowel biopsy specimen taken from a patient
with Whipple’s disease. A search by computer for
similar rRNA sequences filed in databases showed
the Whipple’s-associated organism to be most
similar to bacteria of the Rhodococcus,
Streptomyces, and Arthrobacter genera, and more
weakly related to mycobacteria. The biopsy
specimen was estimated to contain around 107 cells
of the organism. The probable aetiological agent for
our patient’s illness has not been identified
previously in a patient with Whipple’s disease.
Whipple’s disease is a systemic infection associated with a
small, largely intracellular bacillus of uncertain identity.
The nature of the Whipple’s bacillus has not been
established because efforts to culture the organism have
been unsuccessful. We report the results of sequencing the
ribosomal DNA of the predominant bacterium associated
with a biopsy taken from the small bowel of a woman with
Whipple’s disease. Comparison of 16 S rRNA sequences is a
powerful approach to phylogenetic analysis, and had led to a
new phylogenetic tree of all life forms.1 It was thus possible
to place the Whipple’s-associated bacterial organism
(WABO) phylogenetically by comparing its 16 S rRNA
sequence with known sequences.
A 70-year-old woman presented with a 1-year history of
diarrhoea, a 9 kg weight loss, and iron-deficiency anaemia. She
complained of abdominal distension, arthralgia, fatigue, and
myalgia. On physical examination the patient was cachectic with a
distended abdomen and thickening of the metacarpals and wrists.
X-ray examination of the small bowel suggested malabsorption, and
an abdominal computed tomography scan revealed paracaval and
periaortic lymphadenopathy. Upper gastrointestinal endoscopy
showed a bowel mucosa with a granular infiltrated pattern.
Histologically, the small bowel lamina propria was expanded by
foamy macrophages and had prominent lymphatic dilatation.
Material in the macrophages stained periodic acid-Shiff-positive
and did not contain acid-fast organisms. Electron microscopy
showed large numbers of intracellular and extracellular bacilli
characteristic of those found in Whipple’s disease.
After informed consent, an endoscopic biopsy specimen of the
proximal small bowel was taken and frozen rapidly in dry
ice-ethanol. Nucleic acids extracted from the biopsy specimen were
amplified in a polymerase chain reaction (PCR) for 35 cycles. The
PCR primers were designed to amplify specifically a 721-base
segment of bacterial 16 S rDNA (identical to an organism’s rRNA
sequence).2 The resulting PCR product was sequenced directly. A
computer search of the Genbank and EMBI databases was done to
find the rRNA sequences most similar to the one we had isolated,
and all sequences were aligned. The alignment was used to find a
site at which the sequence of the WABO differed from the
